Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2023 06:05 ET | Source: ProKidney

ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference

WINSTON-SALEM, N.C., March 03, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
January 10, 2023 16:05 ET | Source: ProKidney

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease

- Article published online in the Journal of Blood Purification; to be included in future print edition - WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)...
December 22, 2022 06:05 ET | Source: ProKidney

ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference

WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
November 14, 2022 06:05 ET | Source: ProKidney

ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
November 11, 2022 16:05 ET | Source: ProKidney

ProKidney to Participate in Upcoming Investor Conferences

WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
November 03, 2022 06:05 ET | Source: ProKidney

ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease

WINSTON-SALEM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
October 14, 2022 12:00 ET | Source: ProKidney

ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022

- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022 - Investor and analyst scientific briefing to be hosted in...
September 23, 2022 06:15 ET | Source: ProKidney

ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit

WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
September 08, 2022 06:05 ET | Source: ProKidney

ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
August 31, 2022 06:05 ET | Source: ProKidney

ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations

Brings nearly 20 years of investor relations and corporate communications experience to ProKidney WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)...